BridgeMD
New treatment option for Venous Thromboembolism (VTE)
Official title Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism
ClinicalTrials.gov ID: NCT07143539
What this study is testing
- What it's testing
- Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years
- Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary...
- Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission
- Written informed consent
You likely can't join if
- Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary...
- Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)
- Recently completed (i.e., \<6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication
- Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)
- Contraindication to anticoagulation
- Life expectancy \<1 year based on the treating physician's clinical judgement
See the full eligibility criteria
- Age ≥18 years
- Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a...
- Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission
- Written informed consent
- Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)
- Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)
- Recently completed (i.e., \<6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication
- Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)
- Contraindication to anticoagulation
- Life expectancy \<1 year based on the treating physician's clinical judgement
- Known pregnancy
- Inability to speak German or French
- Participation in another study that prohibits concurrent participation in RehabPE
- Unable to provide informed consent (e.g., due to dementia)
- Unwilling to provide informed consent
- Prior enrollment in this study
The study team makes the final eligibility decision.
Where it's taking place
- Aarau, Switzerland
- Baden, Switzerland
- Bern, Switzerland
- Geneva, Switzerland
- Lausanne, Switzerland
- Zurich, Switzerland
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarau, Switzerland; Baden, Switzerland; Bern, Switzerland; Geneva, Switzerland; Lausanne, Switzerland; Zurich, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.